An Open-label, Multi-Centered, Dose Escalation Phase Ib Study (Expansion Stage) of Epitinib (HMPL-813) in Patients With Advanced Solid Tumors

Trial Profile

An Open-label, Multi-Centered, Dose Escalation Phase Ib Study (Expansion Stage) of Epitinib (HMPL-813) in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Epitinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 29 Nov 2016 Results published in the Chi-Med Media Release.
    • 29 Nov 2016 According to Chi-Med media release, results will be presented at the 17th World Conference on Lung Cancer (WCLC)
    • 13 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top